<code id='D60EE9BA4B'></code><style id='D60EE9BA4B'></style>
    • <acronym id='D60EE9BA4B'></acronym>
      <center id='D60EE9BA4B'><center id='D60EE9BA4B'><tfoot id='D60EE9BA4B'></tfoot></center><abbr id='D60EE9BA4B'><dir id='D60EE9BA4B'><tfoot id='D60EE9BA4B'></tfoot><noframes id='D60EE9BA4B'>

    • <optgroup id='D60EE9BA4B'><strike id='D60EE9BA4B'><sup id='D60EE9BA4B'></sup></strike><code id='D60EE9BA4B'></code></optgroup>
        1. <b id='D60EE9BA4B'><label id='D60EE9BA4B'><select id='D60EE9BA4B'><dt id='D60EE9BA4B'><span id='D60EE9BA4B'></span></dt></select></label></b><u id='D60EE9BA4B'></u>
          <i id='D60EE9BA4B'><strike id='D60EE9BA4B'><tt id='D60EE9BA4B'><pre id='D60EE9BA4B'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:54469
          Darron Cummings/AP

          Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

          The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

          advertisement

          Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Merck to buy EyeBio, maker of eye drug, as it grows pipeline
          Merck to buy EyeBio, maker of eye drug, as it grows pipeline

          AdobeLONDON—MercksaidWednesdayitisbuyingophthalmology-focusedstartupEyeBioinadealworthupto$3billion,

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Primary care doctor shortage won't be solved by free med school tuition

          AdobeLastmonth,nearly40,000medicalstudentswereacceptedintoresidencyprogramson“MatchDay.”Surroundedby